CART-19 cells has emerged as a powerful targeted immunotherapy, showing striking responses in
highly refractory CD19+ acute lymphoblastic leukemia (ALL). This study aims to assess the
safety and toxicity of CART-19 cells to patients who are refractory or at highest risk of
relapse as defined by MRD+ status.